What's next in peripartum cardiomyopathy investigation?

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 6, 2010, Pages 743-746

  Fett, James D ^a,b  

^a Hospital Albert Schweitzer   (Haïti)

^b North American Peripartum Cardiomyopathy Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CATHEPSIN D; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN;

CARDIOMYOPATHY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; EDITORIAL; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; PERIPARTUM CARDIOMYOPATHY; PREGNANCY; TREATMENT RESPONSE; VIRUS INFECTION; ADULT; CARDIOMYOPATHIES; FEMALE; PATHOPHYSIOLOGY; POSTNATAL CARE; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL CARE; PROCEDURES; YOUNG ADULT;

ADULT; CARDIOMYOPATHIES; FEMALE; HUMANS; POSTNATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL CARE; YOUNG ADULT;

EID: 77953482546     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.50     Document Type: Editorial

References (68)

1. Tibazarwa K, Sliwa K. Peripartum cardiomyopathy in Africa: challenges in diagnosis, prognosis and therapy. Prog. Cardiovasc. Dis. 52(4), 317-325 (2010).
2. Ramaraj R, Sorrell VL. Peripartum cardiomyopathy: causes, diagnosis and treatment. Cleve. Clin. J. Med. 76(5), 289-296 (2009).
3. Selle T, Renger I, Labidi S, Bultmann I, Hilfiker-Kleiner D. Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol. 5(2), 175-189 (2009).
4. Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int. J. Cardiol. 131, 168-179 (2009).
5. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 368, 687-693 (2006).
6. Pearson GD, Veille JC, Rahiimtoola S et al. Peripartum cardiomyopathy: National Heart, Lung and Blood Institute and Offices of Rare Diseases (National Institutes of Health) Workshop recommendations and review. JAMA 283, 1183-1188 (2000).
7. Elkayam U, Akhter MW, Singh H et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 111, 2050-2055 (2005).
8. Sundstrom JB, Fett JD, Carraway RD, Ansari AA. Is peripartum cardiomyopathy an organ specific autoimmune disease? Autoimmun. Rev. 1, 73-77 (2002).
9. Ansari AA, Fett JD, Caraway RD, Mayne AE, Onlamoon M, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin. Rev. Allergy Immunol. 23, 301-324 (2002).
10. Warraich RS, Fett JD, Damasceno A et al. Impact of pregnancy related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am. Heart. J. 150, 263-269 (2005).
11. Hill SL, Rose NR. The transition from viral to autoimmune myocarditis. Autoimmunity 34, 169-176 (2001).
12. Hilfiker-Kleiner D, Kaminski K, Podewski E et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128, 589-600 (2007).
13. Sliwa K, Blauwet L, Tibazarwa K et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy. A proof-of-concept pilot study. Circulation 121(13), 1465-1473 (2010).
14. Elkayam U, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. Circulation 121, 1463-1464 (2010).
15. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am. Heart. J. 152, 509-513 (2006).
16. Fett JD, Sannon H, Thelisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. Int. J. Gynaecol. Obstet. 104, 125-127 (2009).
17. American Heart Association. The AHA Guidelines and Scientific Statements Handbook. Fuster V (Ed.). Wiley- Blackwell, Oxford, UK (2009).
18. Riordan J. Breastfeeding and Human Lactation (3rd Edition). Jones and Bartlett, MA, USA, 75-77 (2005).
19. McMurray J, Swedberg K. Treatment of chronic heart failure: a comparison between the major guidelines. Eur. Heart J. 27(15), 1773-1777 (2006).
20. Godsel LM, Leon JS, Engman DM. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis. Curr. Pharm. Des. 9, 723-735 (2003).
21. Ohtsuka T, Hamada M, Hiasa G et al. Effect of b-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 37, 412-417 (2001).
22. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 286(1), H83-H90 (2004).
23. Platten M, Youssef S, Hur EM et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates Th1 and Th17-mediated autoimmunity. Proc. Natl Acad. Sci. USA 106, 14948-14953 (2009).
24. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death. Circulation 99, 1091-1100 (1999).
25. Mason JW. Viral latency: a link between myocarditis and dilated cardiomyopathy? J. Mol. Cell Cardiol. 34, 695-698 (2002).
26. Fujioka S, Kitaura Y, Deguchi H et al. Evidence of viral infection in the myocardium of American and Japanese patients with idiopathic dilated cardiomyopathy. Am. J. Cardiol. 94, 602-605 (2004).
27. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am. J. Obstet. Gynecol. 193, 363-365 (2005).
28. Ambrosini G, Nanhornbque K, Pascoli I, Cester M, Cosmi E. Mirror syndrome due to coxsackie B virus associated to maternal peripartum cardiomyopathy. J. Perinat. Med. 36, 453-454 (2008).
29. Fett JD. Diagnosis of viral cardiomyopathy by analysis of peripheral blood? Expert Opin. Ther. Targets 12, 1073-1075 (2008).
30. Muroya T, Ikeda S, Yamasa T et al. High dose immune globulin therapy ameliorates peripartum cardiomyopathy with elevated serum antibody titer to influenza virus: case report of two patients. Med. Sci. Monit. 16(2), CS11-CS14 (2010).
31. Halapas A, Pissimississ N, Lembessis P et al. Molecular diagnosis of the viral component in cardiomyopathies: pathophysiological, clinical and therapeutic implications. Expert Opin. Ther. Targets 12, 821-836 (2008).
32. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur. Heart J. DOI: 10.1093/eurheartj/ehn296 (2008) (Epub ahead of print).
33. Mahrholdt H, Wagner A, Deluigi CC et al. Presentation, patterns of myocardial damage and clinical course of viral myocarditis. Circulation 114, 1581-1590 (2006).
34. Mahrholdt H, Goedecke C, Wagner A et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109, 1250-1258 (2004).
35. Tavora F, Gonzalez-Cuyar LF, Dalal JS et al. Fatal parvoviral myocarditis: a case report and review of literature. Diagn. Pathol. 3, 21 (2008).
36. Tam PY, Butler K, McMahon CJ. Incidental detection of parvovirus myocarditis at time of resection of discrete subaortic stenosis. Cardiol. Young 16, 596-598 (2006).
37. Lamparter S, Schoppet M, Pankuweit S, Maisch B. Acute parvovirus B19 infection associated with myocarditis in an immunocompetent adult. Hum. Pathol. 34, 725-728 (2003).
38. Murry CE, Jerome KR, Reichenbach DD. Fatal parvovirus myocarditis in a 5-year-old girl. Hum. Pathol. 32, 342-345 (2001).
39. Letsas KP, Filippatos GS, Delimpasi S et al. Enterovirus-induced fulminant myocarditis and hemophagocytic syndrome. J. Infect. 54, e75-e77 (2007).
40. Ishikawa T, Zhu BL, Li DR et al. Epstein-Barr virus myocarditis as a cause of sudden death: two autopsy cases. Int. J. Legal Med. 119, 231-235 (2005).
41. Frustaci A, Calabrese F, Chimenti C et al. Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy. Chest 122, 1348-1356 (2002).
42. Harder TC, Hufnagel M, Zahn K et al. New light cycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections. J. Clin. Microbiol. 39, 4413-4419 (2001).
43. Goland S, Czer LS, Siegel RJ et al. Intravenous immunoglobulin in treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can. J. Cardiol. 24, 571-574 (2008).
44. Bozkurt B, Villaneuva S, Holubkov R et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J. Am. Coll. Cardiol. 34, 177-180 (1999).
45. Cooper LT, Virmani R, Chapman NM et al. National Institutes of Health- Sponsored Workshop on Inflammation and Immunity in Dilated Cardiomyopathy. Mayo Clin. Proc. 81, 199-204 (2006).
46. Kaveri SV, Lacroix-Desmazes S, Bayry J. Clinical implications of basic research: the antinflammatory IgG. N. Engl. J. Med. 359, 307-309 (2008).
47. Lindner J, Noutsias M, Lassner D et al. Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J. Clin. Virol. 44, 27-32 (2009).
48. Bock CT, Klingel K, Kanddolf R. Human parvovirus B19-associated myocarditis. N. Engl. J. Med. 362, 1248-1249 (2010).
49. Fett JD, Christie LG, Carraway RD, Ansari AA, Sundstrom JB, Murphy JG. Unrecognized peripartum cardiomyopathy in Haitian women. Int. J. Gynaecol. Obstet. 90, 161-166 (2005).
50. Vettori DV, Rohde LE, Clauself N. Asymptomatic left ventricular dysfunction in puerperal women: an echocardiographic-based study. Int. J. Cardiol. DOI: 10.1016/j.ijcard.2010.01.015 (2010) (Epub ahead of print).
51. Riad A, Westermann D, Escher F et al. Myeloid differentiation factor-88 contributes to TLR9-mediated modulation of acute coxsackievirus B3-induced myocarditis in vivo. Am. J. Physiol. Heart Circ. Physiol. DOI: 10.1152/ ajpheart.01188.2009 (2010) (Epub ahead of print).
52. Jahns R, Boivin V, Hein L et al. Direct evidence for a b1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J. Clin. Invest. 113, 1419-1429 (2004).
53. Freedmann NJ, Lefkowitz RJ. Anti-B1- adrenergic receptor antibodies and heart failure: causation, not just correlation. J. Clin. Invest. 113, 1379-1382 (2004).
54. Fett JD, Ansari AA, Sundstrom JB, Combs GR Jr. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int. J. Cardiol. 86, 311-316 (2002).
55. Muscaro-Blanco A, Alvarez K, Yu X et al. Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity 41, 442-453 (2008).
56. Ellis JE, Ansari AA, Fett JD et al. Inhibition of progenitor dendritic cell maturation by plasma from patients with peripartum cardiomyopathy: role in pregnancy-associated heart disease. Clin. Devel. Immunol. 12, 265-273 (2005).
57. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. C-reactive protein co-expresses with tumor necrosis factor-a in the myocardium in human dilated cardiomyopathy. Eur. J. Heart Fail. 7, 748-754 (2005).
58. Lindberg E, Magnusson Y, Karason K, Andersson B. Lower levels of the host protective IL-10 in DCM - a feature of autoimmune pathogenesis? Autoimmunity 41, 478-483 (2008).
59. Sliwa K, Forster O, Libhaber E et al. Peripartum dardiomyopathy: inflammatory markers as predictors of outcome in 100 propspectively studied patients. Eur. Heart J. 27, 441-446 (2006).
60. Horwitz MS, Knudsen M, Ilic A, Fine C, Sarvetnick N. Transforming growth factor-b inhibits coxsackievirus-mediated autoimmune myocarditis. Viral Immunol. 19, 722-733 (2006).
61. Lucas JA, Zhang Y, Li P et al. Inhibition of transforming growth factor-b signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart. Am. J. Physiol. Heart Circ. Physiol. 298, H424-H432 (2010).
62. Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. J. Am. Coll. Cardiol. 55(7), 654-659 (2010).
63. Brar SS, Khan SS, Sandhu GK et al. Incidence, mortality and racial difference in peripartum cardiomyopathy. Am. J. Cardiol. 100, 302-304 (2007).
64. Fett JD, Christie LG, Murphy JG. Outcomes of subsequent pregnancy after peripartum cardiomyopathy: a case series from Haiti. Ann. Int. Med. 145, 30-34 (2006).
65. Elkayam U, Tummala PP, Rao K et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N. Engl. J. Med. 344(21), 1567-1571 (2001).
66. Habli M, O'Brien T, Nowack E, Khoury S, Barton JR, Sibai B. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am. J. Obstet. Gynecol. 199(4), 415.e1-5 (2008).
67. Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am. J. Obstet. Gynecol. 201(2), 171.e1-e5 (2009).
68. Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int. J. Gynecol. Obstet. 109(1), 34-36 (2010).